Shanghai OPM Biosciences (SH:688293)2024-09-20 08:58Group 1: Investor Relations Activities - The investor relations activity took place on September 18, 2024, at the company meeting room, attended by representatives from Dongwu Securities and Puyin Ansheng [2] - The activity was categorized as a specific object research event [2] Group 2: Company Performance Expectations - The company adjusted its performance expectations in August 2024 due to industry changes and macroeconomic factors [2] - The company has a total of 5 commercialized projects using its culture media as of June 30, 2024, with growth expected, and detailed data will be disclosed in the Q3 2024 report [2] Group 3: CDMO Business Outlook - The CDMO business showed improvement in Q2 compared to Q1, indicating that Q1 was likely the lowest point [3] - The CDMO business is expected to be affected by increased fixed asset depreciation due to the new factory, but recovery is anticipated as the industry stabilizes [3] Group 4: Dividend and Recruitment Plans - The mid-term dividend for 2024 is scheduled to be distributed on September 20, 2024 [3] - Recruitment plans will align with business needs and progress, avoiding blind expansion [3]